JPWO2019135166A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019135166A5 JPWO2019135166A5 JP2020537525A JP2020537525A JPWO2019135166A5 JP WO2019135166 A5 JPWO2019135166 A5 JP WO2019135166A5 JP 2020537525 A JP2020537525 A JP 2020537525A JP 2020537525 A JP2020537525 A JP 2020537525A JP WO2019135166 A5 JPWO2019135166 A5 JP WO2019135166A5
- Authority
- JP
- Japan
- Prior art keywords
- doxycycline
- composition
- item
- administration
- rosacea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 162
- 239000000203 mixture Substances 0.000 claims description 148
- 229960003722 doxycycline Drugs 0.000 claims description 126
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 126
- 201000004700 rosacea Diseases 0.000 claims description 74
- 230000002757 inflammatory effect Effects 0.000 claims description 62
- 241001303601 Rosacea Species 0.000 claims description 54
- 229960004023 minocycline Drugs 0.000 claims description 46
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 46
- 230000003902 lesion Effects 0.000 claims description 44
- 230000036470 plasma concentration Effects 0.000 claims description 20
- 210000003722 extracellular fluid Anatomy 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 10
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 8
- 208000001126 Keratosis Diseases 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 208000003251 Pruritus Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 206010039580 Scar Diseases 0.000 claims description 6
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010016936 Folliculitis Diseases 0.000 claims description 4
- 208000009675 Perioral Dermatitis Diseases 0.000 claims description 4
- 206010052428 Wound Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000008185 minitablet Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 208000010305 Epidermal Cyst Diseases 0.000 claims description 3
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 101100262131 Mus musculus Prss16 gene Proteins 0.000 claims 1
- 206010033733 Papule Diseases 0.000 description 3
- 208000006311 Pyoderma Diseases 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024079573A JP2024098011A (ja) | 2018-01-07 | 2024-05-15 | 炎症性皮膚状態を処置するためのミノサイクリン |
| JP2025219443A JP2026031656A (ja) | 2018-01-07 | 2025-12-02 | 炎症性皮膚状態を処置するためのミノサイクリン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741023993 | 2018-01-07 | ||
| IN201741023993 | 2018-01-07 | ||
| PCT/IB2019/000144 WO2019135166A1 (en) | 2018-01-07 | 2019-01-07 | Minocycline for treating inflammatory skin conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024079573A Division JP2024098011A (ja) | 2018-01-07 | 2024-05-15 | 炎症性皮膚状態を処置するためのミノサイクリン |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021509409A JP2021509409A (ja) | 2021-03-25 |
| JP2021509409A5 JP2021509409A5 (https=) | 2022-01-17 |
| JPWO2019135166A5 true JPWO2019135166A5 (https=) | 2022-01-17 |
| JP7561029B2 JP7561029B2 (ja) | 2024-10-03 |
Family
ID=65269058
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537525A Active JP7561029B2 (ja) | 2018-01-07 | 2019-01-07 | 炎症性皮膚状態を処置するためのミノサイクリン |
| JP2024079573A Pending JP2024098011A (ja) | 2018-01-07 | 2024-05-15 | 炎症性皮膚状態を処置するためのミノサイクリン |
| JP2025219443A Pending JP2026031656A (ja) | 2018-01-07 | 2025-12-02 | 炎症性皮膚状態を処置するためのミノサイクリン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024079573A Pending JP2024098011A (ja) | 2018-01-07 | 2024-05-15 | 炎症性皮膚状態を処置するためのミノサイクリン |
| JP2025219443A Pending JP2026031656A (ja) | 2018-01-07 | 2025-12-02 | 炎症性皮膚状態を処置するためのミノサイクリン |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11191740B2 (https=) |
| EP (1) | EP3735249A1 (https=) |
| JP (3) | JP7561029B2 (https=) |
| KR (1) | KR102705507B1 (https=) |
| CN (1) | CN111818927A (https=) |
| AU (2) | AU2019205134B9 (https=) |
| BR (1) | BR112020013789A2 (https=) |
| CA (1) | CA3087838A1 (https=) |
| EA (1) | EA202091653A1 (https=) |
| MX (1) | MX2020007222A (https=) |
| WO (1) | WO2019135166A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7561029B2 (ja) | 2018-01-07 | 2024-10-03 | ドクター レディズ ラボラトリーズ リミテッド | 炎症性皮膚状態を処置するためのミノサイクリン |
| CA3106884C (en) * | 2018-07-19 | 2025-04-01 | Doosan Bobcat North America, Inc. | DISPLAY POSITION FOR CABIN WITH TILTING DOOR |
| CN120324439A (zh) * | 2025-03-05 | 2025-07-18 | 福安药业集团宁波天衡制药有限公司 | 一种稳定的盐酸米诺环素胶囊及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1383508B1 (en) * | 2001-04-05 | 2006-06-21 | Collagenex Pharmaceuticals, Inc. | Doxycycline for the treatment of acne |
| US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| EP1494681A4 (en) * | 2002-04-16 | 2008-08-06 | Collagenex Pharm Inc | PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20140186269A1 (en) | 2013-01-03 | 2014-07-03 | Foamix Ltd. | Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| PT106679B (pt) | 2012-11-27 | 2015-03-25 | Hovione Farmaciencia Sa | Formulações tópicas de tetraciclinas, sua preparação e usos |
| JP7561029B2 (ja) | 2018-01-07 | 2024-10-03 | ドクター レディズ ラボラトリーズ リミテッド | 炎症性皮膚状態を処置するためのミノサイクリン |
-
2019
- 2019-01-07 JP JP2020537525A patent/JP7561029B2/ja active Active
- 2019-01-07 AU AU2019205134A patent/AU2019205134B9/en active Active
- 2019-01-07 CA CA3087838A patent/CA3087838A1/en active Pending
- 2019-01-07 BR BR112020013789-8A patent/BR112020013789A2/pt not_active Application Discontinuation
- 2019-01-07 MX MX2020007222A patent/MX2020007222A/es unknown
- 2019-01-07 WO PCT/IB2019/000144 patent/WO2019135166A1/en not_active Ceased
- 2019-01-07 CN CN201980017148.7A patent/CN111818927A/zh active Pending
- 2019-01-07 KR KR1020207022760A patent/KR102705507B1/ko active Active
- 2019-01-07 EP EP19714476.9A patent/EP3735249A1/en active Pending
- 2019-01-07 US US16/241,754 patent/US11191740B2/en active Active
- 2019-01-07 EA EA202091653A patent/EA202091653A1/ru unknown
-
2020
- 2020-03-23 US US16/827,622 patent/US10905664B2/en active Active
- 2020-12-23 US US17/132,825 patent/US11364212B2/en active Active
-
2022
- 2022-06-20 US US17/844,715 patent/US12594252B2/en active Active
-
2024
- 2024-05-15 JP JP2024079573A patent/JP2024098011A/ja active Pending
-
2025
- 2025-02-06 AU AU2025200826A patent/AU2025200826A1/en active Pending
- 2025-12-02 JP JP2025219443A patent/JP2026031656A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101667762B1 (ko) | 엔타카폰 또는 이의 염의 서방형 약학 조성물 | |
| NO328797B1 (no) | Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt. | |
| KR20100099731A (ko) | 레보도파 방출 제어형 제제 및 이의 용도 | |
| JP2015522630A (ja) | 多発性硬化症治療のためのビオチンの使用 | |
| AU2014212109B2 (en) | Compositions and methods for the treatment of neurodegenerative and other diseases | |
| EP1849462A2 (en) | A method of alleviating signs and symptons of Spasticity | |
| CN112638378A (zh) | 用于根除幽门螺杆菌的组合物 | |
| US20210236488A1 (en) | Imatinib for use in the treatment of stroke | |
| JP2023544420A (ja) | ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物 | |
| Guada et al. | Cyclosporine A-loaded lipid nanoparticles in inflammatory bowel disease | |
| WO2011019845A1 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| US10570083B2 (en) | Compositions comprising oxo-derivatives of fatty acids and methods of making and using same | |
| EP4598530A1 (en) | Methods and compositions for treating hidradenitis suppurativa | |
| JP2021509409A5 (https=) | ||
| JPWO2019135166A5 (https=) | ||
| JP2021509409A (ja) | 炎症性皮膚状態を処置するためのミノサイクリン | |
| US20240100011A1 (en) | Pediatric formulations of ferric citrate | |
| CN113164377A (zh) | 用于治疗炎性、纤维化和增生性病状的dgla和/或15-hetre | |
| AU2016368299A1 (en) | Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof | |
| US9649289B1 (en) | Method and composition for treating dysbiosis and related disease states | |
| Sun et al. | Treatment of acute intracerebral haemorrhage with a Chinese herbal formula (Shengdi Dahuang Decoction): a multicentre, double-blind, randomised, placebo-controlled trial | |
| EA029932B1 (ru) | Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции | |
| TW202133849A (zh) | 一種吡嗪醯胺化合物ｂｃｔｃ用於製備治療或改善神經退化症及中風的醫藥組合物的用途 | |
| EP4539836A1 (en) | Novel combination based on salified butyric acid and yeasts, compositions containing it and their use in therapy | |
| CN119325372A (zh) | 间苯三酚制剂和使用方法 |